

Cytochrome P450 1A1 and Manganese Superoxide Dismutase Gene Polymorphisms in Behçet's Disease

JENG-HSIEN YEN, WEN-CHUN TSAI, CHIA-HUI LIN, TSAN-TENG OU, CHAUR-JONG HU, and HONG-WEN LIU

ABSTRACT. *Objective.* To investigate the association of cytochrome p450 1A1 (CYP1A1) and manganese superoxide dismutase (MnSOD) gene polymorphisms with susceptibility to Behçet's disease (BD) in Taiwan.

Methods. The polymorphisms of CYP1A1 and MnSOD genes were determined in 51 patients with BD and 91 healthy controls by polymerase chain reaction/restriction fragment length polymorphism methods.

Results. The frequencies of CYP1A1 4889G and 4887A were significantly increased in patients with BD. In contrast, there was no significant difference in the frequencies of MnSOD gene polymorphisms between patients with BD and controls. Linkage disequilibrium was found between CYP1A1 4889G and CYP1A1 6235C in controls and patients with BD. However, a similar finding could not be found between CYP1A1 4889G and 4887A. We also found that the association of CYP1A1 4889G with BD was dependent on the presence of CYP1A1 4887A. On the other hand, the association of CYP1A1 4887A with BD was dependent on the presence of CYP1A1 4889G. An additive effect of CYP1A1 4889G and 4887A on the susceptibility to BD could be found.

Conclusion. Simultaneous presence of CYP1A1 4889G and 4887A is associated with development of BD in Taiwan. (J Rheumatol 2004;31:736–40)

Key Indexing Terms:

MANGANESE SUPEROXIDE DISMUTASE

CYTOCHROME

BEHÇET'S DISEASE

Behçet's disease (BD) is a chronic relapsing inflammatory disease with multiple organ involvement. The most common clinical manifestations are recurrent oral ulcers and genital ulcers. The less common features include central nervous system involvement, arterial aneurysms, mucosal ulceration of intestinal tract, and deep vein phlebitis¹. BD is common in eastern Asia, Japan, and the Mediterranean Basin², but it is relatively uncommon in Taiwan.

The etiology of BD is still unknown. Genetic factors play an important role in pathogenesis of BD³. Although the association of HLA-B51 with BD was noted in Japanese⁴, no consistent HLA association has been found in other populations⁵. Thus non-HLA genes may also be related to the pathogenesis of BD.

Smoking is a risk factor for vascular involvement in BD⁶.

Cytochrome P450 1A1 (CYP1A1) plays an important role in the metabolism of tobacco-derived polycyclic aromatic hydrocarbons (PAH)⁷. CYP1A1 may catalyze activation of PAH to reactive metabolites that initiate damage to DNA⁸. Thus, CYP1A1 may also be related to the pathogenesis of BD. In our previous study, CYP1A1 gene polymorphisms were associated with the development of systemic lupus erythematosus (SLE)⁹. However, the association between CYP1A1 gene polymorphisms and BD is still unknown.

Cytochrome p450 (CYP) is a member of a superfamily of enzymes that catalyze oxidation of various xenobiotics including drugs, toxic chemicals, and carcinogens^{10,11}. Most CYP metabolism results in the detoxification of xenobiotics, while some chemicals are activated¹². The superoxide radical is produced in the detoxification process of CYP¹³.

The reactive oxygen species are involved in the pathogenesis of BD^{14–16}. Enhanced superoxide generation and decreased superoxide scavenging activity of peripheral blood leukocytes can be found in BD¹⁷. Serum from patients with BD also enhances superoxide production of normal neutrophils¹⁸. The decreased superoxide scavenging activity will lead to accumulation of superoxide radical, and this induces tissue damage. Superoxide dismutase (SOD) is a scavenger of reactive oxygen species. There are 3 isoenzymes of SOD including MnSOD, CuZnSOD, and FeSOD. MnSOD is an antioxidant enzyme that protects against free radical-induced cytotoxicity¹⁹. Thus, MnSOD may also be related to the pathogenesis of BD.

We investigated the roles of CYP1A1 and MnSOD gene polymorphisms in the pathogenesis of BD in Taiwan.

From the Division of Rheumatology, Department of Internal Medicine, Kaohsiung Medical University Hospital; Department of Medicine, Kaohsiung Municipal United Hospital; Department of Internal Medicine, Kaohsiung Municipal Hsiao-Kang Hospital; and the Molecular Medicine Laboratory, Taipei Municipal Jen-Ai Hospital, Taiwan.

J-H. Yen, MD, PhD, MSc, Professor, Division of Rheumatology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Department of Medicine, Kaohsiung Municipal United Hospital; W-C. Tsai, MD, PhD, Associate Professor; C-H. Lin, Technician; T-T. Ou, MD, Attending Physician; H-W. Liu, MD, Division of Rheumatology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Professor, Kaohsiung Medical University; C-J. Hu, MD, Lecturer, Molecular Medicine Laboratory, Taipei Municipal Jen-Ai Hospital.

Address reprint requests to Dr. J-H. Yen, No. 100 Shih-Chuan 1st Road, Kaohsiung City 807, Taiwan. E-mail: jehsy@kmu.edu.tw

Submitted January 20, 2003; revision accepted September 26, 2003.

MATERIALS AND METHODS

Fifty-one patients with BD and 91 healthy controls were enrolled in this study. All patients fulfilled the International Study Group criteria for the diagnosis of BD²⁰. All patients and healthy controls were Taiwanese.

Polymorphisms of CYP1A1 gene. There are several CYP1A1 gene polymorphisms including 6235 T→C (3' noncoding), 5639 T→C (intron 7), 4889 A→G (exon 7, codon 462 Ile→Val), and 4887 C→A (exon 7, codon 461 Thr→Asn). CYP1A1 polymorphisms were determined by the polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) method. The sequences of primers for polymorphisms at nucleotide position 6235 were 5'-GGCTGAGCAATCTGACCCTA-3' and 5'-TAGGAGTCTTGTCTCATGCCT-3'. After PCR, the PCR product was digested with MspI. A sequence with 6235C can be cleaved with MspI. The sequences of primers for polymorphisms at nucleotide positions 4889 and 4887 were 5'-CTGTCTCCCTCTGGTTACAGGAGC-3' and 5'-TTCCACCCGTTGCAGCAG GATAGCC-3'. After PCR, the product was digested with BsrDI and BsaI for polymorphisms at positions 4889 and 4887, respectively. The sequences with 4889A and 4887C can be cleaved with BsrDI and BsaI, respectively. The sequences of primers for polymorphisms at nucleotide position 5639 were 5'-GGCTGAGCAATCTGACCCTA-3' and 5'-GAAGGGAGACCAATAGAAGG-3'. After PCR, the product was digested with MspI, and a sequence with 5639C can be cleaved with MspI.

Polymorphisms of MnSOD gene. There are 2 polymorphic sites in the MnSOD gene, C1183T (Ala-9 Val) and T5777C (Ile 58 Thr). The C1183T (Ala-9 Val) polymorphisms were determined by PCR/RFLP. The sequences of primers were 5'-AGCCCAGCCTGCGTAGAC-3' and 5'-TACTTCTCCTCGGTGACG-3'. The PCR product was digested with BsaWI. A sequence with 1183T, valine at the 9th amino acid of the mitochondrial targeting sequence, can be cleaved with BsaWI. T5777C (Ile 58 Thr) polymorphisms were also determined by PCR/RFLP. A set of primers with a mismatched nucleotide (underlined here) was used. The sequence of primers was 5'-CGGATGTTATAGATAAGCTGG-3' and 5'-CAGTGCAGGCTGAAGAGAT-3'. The PCR product was digested with EcoRV. A sequence with 5777T, isoleucine at the 58th amino acid, can be cleaved with EcoRV.

Statistical analysis. The chi-square test with Yates' correction or Fisher's exact test was used for statistical analysis. Delta values were determined for evaluating the possibility of linkage disequilibrium. Interactions of different CYP1A1 gene polymorphisms were analyzed according to Svejgaard and Ryder²¹.

RESULTS

The characteristics of patients and controls are given in Table 1. The prevalence of BD was more common in men

Table 1. Characteristics of patients with Behçet's disease and controls.

	BD, n (%)	Controls, n (%)
	51	91
Age*, mean ± SD, yrs	44 ± 12	42 ± 8
Sex*		
Male	34 (66.7)	63 (69.2)
Female	17 (33.3)	28 (30.8)
Recurrent oral ulcer	51 (100)	
Recurrent genital ulcer	30 (58.8)	
Skin lesion	42 (82.4)	
Uveitis	11 (21.6)	
Pathergy test	4 (7.8)	

* There were no significant differences in age or sex between patients and controls.

than in women. Table 2 shows the frequencies of CYP1A1 gene polymorphisms in patients and controls. The genotype frequencies of CYP1A1 4889A/G and 4887C/A were significantly higher in patients than in controls. The allele frequencies of CYP1A1 4889G and 4887A were also significantly increased in patients. A similar finding could also be observed in phenotype frequencies of CYP1A1 4889G and 4887A.

There were no significant differences in the genotype and allele frequencies of MnSOD C1183T polymorphisms between patients and controls (Table 3).

Linkage disequilibrium among CYP1A1 gene polymorphisms in controls and patients are given in Table 4. Linkage disequilibrium were found between CYP1A1 4889G and CYP1A1 6235C in patients and controls. However, there were no linkage disequilibrium between CYP1A1 4887A and CYP1A1 4889G.

In the stratification for CYP1A1 4889G, the phenotype frequency of CYP1A1 4887A was significantly higher in CYP1A1 4889G(+) patients than in 4889G(+) controls, but not in 4889G(-) patients and controls (Table 5). In the stratification for CYP1A1 4887A, the phenotype frequency of CYP1A1 4889G was significantly higher in CYP1A1 4887A(+) patients than in 4887A(+) controls, but not in 4887A(-) patients and controls. Thus, the association of CYP1A1 4887A with BD depended on the presence of CYP1A1 4889G. In contrast, the association of CYP1A1 4889G with BD was dependent on the presence of CYP1A1 4887A.

The interactions between CYP1A1 4887A and 4889G in patients and controls are shown in Table 6. The odds ratio was higher in 4887A(+) 4889G(+) than in 4887A(+) 4889G(-) and 4887A(-) 4889G(+) in comparison to 4887A(-) 4889G(-). An additive effect on the susceptibility to BD could be found between 4887A and 4889G.

DISCUSSION

Patients with BD and healthy controls enrolled in this study were ethnically homogenous. The genotype frequencies of CYP1A1 and MnSOD achieved Hardy-Weinberg equilibrium. In this study, men with BD were more common than women with BD, which is compatible with results for the Middle East. The male:female ratio was about 2:1. Vascular involvement is common in BD. In addition to small-vessel vasculitis that accounts for much of the pathology, large-vessel lesions occur in about 25% of Turkish patients²². However, we found only 2 patients with deep vein thrombosis, and one patient had superficial thrombophlebitis. Large-vessel lesions were relatively uncommon in our patients.

CYP1A1 gene is located on the long arm of chromosome 15 (q22-24). The polymorphisms of CYP1A1 gene were related to the development of several malignancies²³⁻²⁷. To date there is no report about associations of CYP1A1 gene polymorphisms with BD. In this study, the genotype frequencies of CYP1A1 4889A/G and 4887C/A were signif-

Table 2. Frequencies of CYP1A1 gene polymorphisms in patients with Behçet's disease and controls.

CYP1A1 Polymorphisms	BD, n = 51 (%)	Controls, n = 91 (%)	OR (95% CI)	p
Genotype frequencies				
CYP1A1 T6235C				
T/T	18 (35.3)	33 (36.3)	0.9 (0.5–1.9)	NS
T/C	25 (49.0)	46 (50.5)	0.9 (0.5–1.8)	NS
C/C	8 (15.7)	12 (13.2)	1.2 (0.5–3.2)	NS
CYP1A1 A4889G				
A/A	17 (33.3)	51 (56.0)	0.4 (0.2–0.8)	0.007
A/G	31 (60.8)	36 (39.6)	2.4 (1.2–4.8)	0.01
G/G	3 (5.9)	4 (4.4)	1.4 (0.3–6.3)	NS
CYP1A1 C4887A				
C/C	17 (33.3)	58 (63.7)	0.3 (1.1–5.9)	0.004
C/A	33 (64.7)	32 (35.2)	3.4 (1.7–6.9)	0.0006
A/A	1 (2.0)	1 (1.1)	1.8 (0.1–29.4)	NS
Allele frequencies				
CYP1A1 T6235C				
T	61 (59.8)	112 (61.5)	0.9 (0.6–1.5)	NS
C	41 (40.2)	70 (38.5)	1.1 (0.7–1.8)	NS
CYP1A1 A4889G				
A	65 (63.7)	138 (75.8)	0.6 (0.3–0.9)	0.03
G	37 (36.3)	44 (24.2)	1.8 (1.1–3.0)	0.03
CYP1A1 C4887A				
C	67 (65.7)	148 (81.3)	0.4 (0.3–0.8)	0.003
A	35 (34.3)	34 (18.7)	2.3 (1.3–3.9)	0.003

NS: not significant.

Table 3. Frequencies of MnSOD gene polymorphisms in patients with Behçet's disease and controls.

MnSOD C1183T (Ala-9Val)	BD, n = 51 (%)	Controls, n = 91 (%)	OR (95% CI)
Genotype frequencies			
C/C	3 (5.9)	3 (3.3)	1.8 (0.4–9.4)
C/T	16 (31.4)	30 (33.0)	0.9 (0.5–1.9)
T/T	32 (62.7)	58 (63.7)	0.6 (0.3–1.2)
Allele frequencies			
C	22 (21.6)	36 (19.8)	1.1 (0.6–2.0)
T	80 (78.4)	146 (80.2)	0.9 (0.5–1.6)

The differences of MnSOD C1183T polymorphisms between patients with BD and controls were not significant.

icantly higher in patients with BD than in controls. The allele frequencies of CYP1A1 4889G and 4887A were also significantly increased in patients with BD. Therefore, CYP1A1 4889G and 4887A may be precipitating factors for the development of BD. However, our study revealed the association of CYP1A1 4887A with BD was dependent on the presence of CYP1A1 4889G. The association of CYP1A1 4889G with BD was also dependent on the presence of CYP1A1 4887A. Thus, presence of 4887A and 4889G simultaneously is associated with the development of BD. A synergistic effect on the susceptibility to BD can be found between 4887A and 4889G. In our previous study, the increased frequency of CYP1A1 4887A could also be found in patients with SLE⁹.

Polymorphisms of CYP1A1 gene at nucleotide positions 6235 and 4889 may lead to higher basal and inducible

Table 4. Linkage disequilibria among polymorphisms of CYP1A1 in controls and patients with Behçet's disease.

Allele 1	Allele 2	Δ	p
Controls			
CYP1A1 4889G	CYP1A1 6235C	0.1	< 0.0001
CYP1A1 4887A	CYP1A1 4889G	0.01	NS
BD			
CYP1A1 4889G	CYP1A1 6235C	0.1	0.015
CYP1A1 4887A	CYP1A1 4889G	–0.8	NS

enzyme activity²⁸ that will enhance the formation of reactive metabolites and induce cell damage. However, the significance of polymorphisms at nucleotide position 4887 is still unknown. The polymorphism at nucleotide position 4887 may also have a similar effect. The linkage disequilibrium

Table 5. Phenotype frequencies of CYP1A1 4887A and 4889G in patients with Behçet's disease and controls stratified by CYP1A1 4889G and 4887A.

	CYP1A1 4889G (+)		OR (95% CI)	p	CYP1A1 4889G (-)		OR (95% CI)	p
	BD	Controls			BD	Controls		
CYP1A1 4887A								
+	23	16	3.1 (1.2–8.2)	0.02	9	17	2.3 (0.7–6.9)	NS
–	11	24			8	34		
	CYP1A1 4887A (+)		OR (95% CI)	p	CYP1A1 4887A (-)		OR (95% CI)	p
	BD	Controls			BD	Controls		
CYP1A1 4889G								
+	23	16	2.7 (1.0–7.6)	0.04	11	24	1.9 (0.7–5.6)	NS
–	9	17			8	34		

Table 6. Interactions between CYP1A1 4887A and 4889G in patients with Behçet's disease and controls.

CYP1A1	BD	Controls	OR (95% CI)	p
4887A (-) 4889G (-)	8	34		
4887A (+) 4889G (-)	9	17	2.3 (0.7–6.9)	NS
4887A (-) 4889G (+)	11	24	1.9 (0.7–5.6)	NS
4887A (+) 4889G (+)	23	16	6.1 (2.3–16.6)	0.0002

between CYP1A1 4889G and 6235C was found in healthy controls and patients with BD, while a similar finding was not found between CYP1A1 4889G and 4887A. The CYP1A1 C4887A and A4889G polymorphisms are in exon 7, known to be related to the enzyme activity of CYP1A1²⁸. Therefore, the polymorphisms of exon 7 may play a role in the pathogenesis of BD. Smoking is a risk factor for developing vasculitis in BD, and CYP1A1 plays a role in the metabolism of tobacco-derived PAH. However, only 3 patients had a smoking history among our patients. An investigation of gene-smoking interaction could not be performed due to the small number of cases.

Patients with BD have enhanced superoxide production and decreased superoxide scavenging activity¹⁷. SOD defends cells against oxidative damage and plays an important role in controlling reactive oxygen and other radical species in cells²⁹. MnSOD is tetrameric and inducible, and is located in human mitochondria³⁰. MnSOD is also the primary defense against reactive oxygen in mitochondria, and it plays an important role in preventing the development of late-onset diseases³¹. Defects of mitochondria are associated with the degenerative diseases of aging such as Parkinson's disease and Alzheimer's disease^{32,33}.

MnSOD gene is on the long arm of chromosome 6 (6q25). The MnSOD gene with thymidine at nucleotide position 5777 encodes a native form of MnSOD that has a stable tetrameric interface. However, MnSOD gene with nucleotide sequence 5777C encodes a mutant form, which has increased thermal instability and accelerated thermal inactivation^{30,34}. The transport of MnSOD into mitochondria

is mediated through interaction of the mitochondrial targeting sequence with receptors on the mitochondrial membrane. The C1183T (Ala-9 Val) polymorphism in the mitochondrial targeting sequence may influence the efficiency of MnSOD transport. The -9 Ala polymorphism results in the formation of α -helix and the -9 Val takes a β -sheet structure³⁵. The α -helix structure is important for the effective transport of precursor proteins into mitochondria³⁶. The amino acid substitution (Ala/Val) at position -9 of the mitochondrial targeting sequence may lead to misdirected trafficking, followed by alteration of MnSOD activity in human mitochondria³⁷. Polymorphisms of MnSOD gene have been reported to be related to several diseases including Parkinson's disease, diabetes mellitus, and malignancies^{35,38-42}. In this study, the MnSOD gene alone was not associated with susceptibility to BD. The MnSOD 5777T polymorphism could not be found in patients with BD or healthy controls in Taiwan. We also found MnSOD and CYP1A1 polymorphisms were not associated with the clinical manifestations of BD (data not shown).

In summary, the simultaneous presence of CYP1A1 4889G and 4887A polymorphisms is associated with susceptibility to Behçet's disease in Taiwan.

REFERENCES

- Ghate JV, Jorizzo JL. Behçet's disease. In: Ruddy S, Harris ED Jr, Sledge CB, editors. Kelley's textbook of rheumatology. Philadelphia: W.B. Saunders; 2002:1205-9.
- James DG. Silk route disease. Post Grad Med J 1986;62:151-3.
- Kaya TI, Dur H, Tersen U, Gurler A. Association of class I HLA antigens with the clinical manifestations of Turkish patients with

- Behçet's disease. *Clin Exp Dermatol* 2002;27:498-501.
4. Mizuki N, Ota M, Katsuyama Y, et al. HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behçet's disease. *Tissue Antigens* 2001;58:181-4.
 5. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR. Behçet's disease, the Silk Road and HLA-B51: historical and geographical perspective. *Tissue Antigens* 1999;54:213-20.
 6. Siepmann M, Kirch W. Coronary anomaly in Behçet's disease. *Rheumatol Int* 1997;17:39-42.
 7. Fryer AA, Jones PW. Interactions between detoxifying enzyme polymorphisms and susceptibility to cancer. In: Ryder W, editor. *Molecular polymorphisms and susceptibility to cancer*. Lyon: IARC Scientific Publications; 1999:303-22.
 8. Larsen MC, Angus WGR, Brake PB, Eltom SE, Sukow KA, Jefcoate CR. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. *Cancer Res* 1998;58:2366-74.
 9. Yen JH, Tsai WC, Chen CJ, et al. Cytochrome P450 and manganese superoxide dismutase genes polymorphisms in systemic lupus erythematosus. *Immunol Lett* 2003;90:19-24.
 10. Daly AK. Molecular basis of polymorphic drug metabolism. *J Mol Med* 1995;73:539-53.
 11. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. *Chem Res Toxicol* 1991;4:391-407.
 12. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi SI. The CYP1A1 gene and cancer susceptibility. *Crit Rev Oncol Hematol* 1993;14:77-87.
 13. Puntarulo S, Cederbaum AI. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes. *Free Radic Biol Med* 1998;24:1324-30.
 14. Kiraz S, Ertenli I, Calguneri M, et al. Interactions of nitric oxide and superoxide dismutase in Behçet's disease. *Clin Exp Rheumatol* 2001;19 Suppl 24:S25-9.
 15. Kose K, Yazici C, Cambay N, Asciglu O, Dogan P. Lipid peroxidation and erythrocyte antioxidant enzymes in patients with Behçet's disease. *Tohoku J Exp Med* 2002;197:9-16.
 16. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. *J Rheumatol* 1993;20:1544-9.
 17. Pronai L, Ichikawa Y, Nakazawa H, Arimori S. Enhanced superoxide generation and the decreased superoxide scavenging activity of peripheral blood leukocytes in Behçet's disease — effects of colchicines. *Clin Exp Rheumatol* 1991;9:227-33.
 18. Yoshida T, Tanaka M, Sotomatsu A, Okamoto K, Hirai S. Serum of Behçet's disease enhances superoxide production of normal neutrophils. *Free Radic Res* 1998;28:39-44.
 19. St. Clair DK, Jordan JA, Wan XS. Protective role of manganese superoxide dismutase against cigarette smoke-induced cytotoxicity. *J Toxicol Environ Health* 1994;43:239-49.
 20. International Study Group for Behçet's disease. Criteria for the diagnosis of Behçet's disease. *Lancet* 1990;335:1078-80.
 21. Svejgaard A, Ryder LP. HLA and disease associations; detecting the strongest association. *Tissue Antigens* 1994;43:18-27.
 22. Koç Y, Güllü I, Akpek G, et al. Vascular involvement in Behçet's disease. *J Rheumatol* 1992;19:402-10.
 23. Yu MW, Chiu YH, Yang SY, et al. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. *Br J Cancer* 1999;80:598-603.
 24. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S. Lung cancer risk and CYP1A1 genotype in African Americans. *Carcinogenesis* 1998;19:813-7.
 25. Krajcinovic M, Ghadirian P, Richer C, et al. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. *Int J Cancer* 2001;92:220-5.
 26. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. *Cancer Lett* 2001;165:171-7.
 27. Nair U, Bartsch H. Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. *IARC Science Publication* 2001;154:271-90.
 28. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. *Carcinogenesis* 1994;15:2961-3.
 29. Winterbourn CC. Superoxide as an intracellular radical sink. *Free Radic Biol Med* 1993;14:85-90.
 30. Borgstahl GE, Parge HE, Hickey MJ, Beyer WF Jr, Hallewell RA, Tainer JA. The structure of human mitochondrial manganese superoxide dismutase reveals a novel tetrameric interface of two 4-helix bundles. *Cell* 1992;71:107-18.
 31. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. *Proc Natl Acad Sci USA* 1993;90:7915-22.
 32. Calabrese V, Scapagnini G, Giuffrida Stella AM, Bates TE, Clark JB. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. *Neurochem Res* 2001;26:739-64.
 33. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. *J Neurosci* 2001;21:3017-23.
 34. Borgstahl GE, Parge HE, Hickey MJ, et al. Human mitochondrial manganese superoxide dismutase polymorphic variant Ile58Thr reduces activity by destabilizing the tetrameric interface. *Biochemistry* 1996;35:4287-97.
 35. Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. *Biochem Biophys Res Commun* 1996;226:561-5.
 36. Lemire BD, Fankhauser C, Baker A, Schatz G. The mitochondrial targeting function of randomly generated peptide sequences correlates with predicted helical amphiphilicity. *J Biol Chem* 1989;264:20206-15.
 37. Shimoda-Matsubayashi S, Hattori T, Matsumine H, et al. MnSOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. *Neurology* 1997;49:1257-62.
 38. Grasbon-Frodl EM, Kösel S, Riess O, Müller U, Mehraein P, Graeber MB. Analysis of mitochondrial targeting sequence and coding region polymorphisms of the manganese superoxide dismutase gene in German Parkinson disease patients. *Biochem Biophys Res Commun* 1999;255:749-52.
 39. Pociot F, Lorenzen T, Nerup J. A manganese superoxide dismutase (SOD2) gene polymorphism in insulin-dependent diabetes mellitus. *Dis Markers* 1993;11:267-74.
 40. Pociot F, Ronningen KS, Bergholdt R, et al. Genetic susceptibility markers in Danish patients with type 1 (insulin-dependent) diabetes — evidence for polygenicity in man. *Autoimmunity* 1994;19:169-78.
 41. Ambrosone CB, Freudenheim JL, Thompson PA, et al. Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. *Cancer Res* 1999;59:602-6.
 42. Izutani R, Asano S, Imano M, Kuroda D, Kato M, Ohyanagi H. Expression of manganese superoxide dismutase in esophageal and gastric cancers. *J Gastroenterol* 1998;33:816-22.